{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:55Z","timestamp":1777878355496,"version":"3.51.4"},"reference-count":55,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-001, 2022-PUMCH-B-013, C-002, D-009"],"award-info":[{"award-number":["2025-PUMCH-D-001, 2022-PUMCH-B-013, C-002, D-009"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32441090"],"award-info":[{"award-number":["32441090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No.Z201100005520022,23, 25-27"],"award-info":[{"award-number":["No.Z201100005520022,23, 25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007225","name":"ministry of science and technology","doi-asserted-by":"publisher","award":["2021YFC2501300, 2021YFC2501304"],"award-info":[{"award-number":["2021YFC2501300, 2021YFC2501304"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005, 2022-I2M-1-004, 2023-I2M-2-005"],"award-info":[{"award-number":["2021-I2M-1-005, 2022-I2M-1-004, 2023-I2M-2-005"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Connective tissue diseases (CTDs) are a group of autoimmune disorders in which immune thrombocytopenia (ITP) represents a common and important manifestation. Current CTD-ITP management mainly relies on glucocorticoids and immunosuppressive agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis aims to evaluate the efficacy and safety of immunosuppressive agents in patients with CTD-ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study was conducted using eight databases up to July 22, 2024. Observational studies and experimental trials with relevant efficacy and safety data were included. Methodological quality were evaluated using the Newcastle-Ottawa Scale and the ROBINS-I tool. The Mantel\u2013Haenszel formula with a random effect model was employed to estimate the overall effect size. Subgroup analyses were performed based on the study characteristics, clinical features, and treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Through integrating 24 studies (1 single-arm clinical trial, 1 case\u2013control, and 22 cohort studies) involving 775 CTD-ITP patients, the pooled estimates of the optimal overall and complete response rate for immunosuppressive therapy were 82% (95% CI: 75\u201388) and 64% (95% CI: 56\u201372), with stable results after sensitivity analysis. The combined side-effect incidence was 31% (95% CI: 24\u201339). The pooled relapse rate was 30% (95% CI: 18\u201343) among 403 immunosuppressive therapy responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Immunosuppressive treatments exhibited favorable efficacy and safety in CTD-ITP patients. Future larger-scale multicenter studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261422963","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T17:26:50Z","timestamp":1772299610000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-1071","authenticated-orcid":false,"given":"Yupei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaxiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa A.","family":"Grimshaw","sequence":"additional","affiliation":[{"name":"Harvey Cushing\/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Bio-Statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Allergy &amp; Immunology, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5287-8593","authenticated-orcid":false,"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Wangfujing Avenue, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14811"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102887"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217356"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1515\/rir-2025-0017"},{"issue":"12","key":"e_1_3_4_8_2","first-page":"2245","article-title":"Factors associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective study of 639 cases","volume":"40","author":"Luo J","year":"2022","unstructured":"Luo J, Song WJ, Chen JQ, et al. Factors associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective study of 639 cases. Clin Exp Rheumatol 2022; 40(12): 2245\u20132252.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08817-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22376"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06641-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab925"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","unstructured":"Haddaway NR Grainger MJ Gray CT. Citationchaser: an R package for forward and backward citations chasing in academic searching. 2021.","DOI":"10.32614\/CRAN.package.citationchaser"},{"key":"e_1_3_4_16_2","unstructured":"Yale University Harvey Cushing\/John Hay Whitney Medical L. Reference deduplicator. Yale University https:\/\/library.medicine.yale.edu\/reference-deduplicator\/(2021 accessed 22 July 2024)."},{"key":"e_1_3_4_17_2","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.","journal-title":"BMJ"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313485489"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315578764"},{"issue":"2","key":"e_1_3_4_22_2","first-page":"82","article-title":"Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus","volume":"6","author":"Calder\u00f3n Saldierna RE","year":"2010","unstructured":"Calder\u00f3n Saldierna RE, Ramos S\u00e1nchez MA, Mej\u00eda Holgu\u00edn Y, et al. Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus. Reumatol Cl\u00edn 2010; 6(2): 82\u201385.","journal-title":"Reumatol Cl\u00edn"},{"issue":"5","key":"e_1_3_4_23_2","first-page":"826","article-title":"Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus","volume":"35","author":"Lindholm C","year":"2008","unstructured":"Lindholm C, B\u00f6rjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35(5): 826\u2013833.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker176"},{"issue":"2","key":"e_1_3_4_25_2","first-page":"139","article-title":"Low-dose rituximab therapy for refractory thrombocytopenia in patients with lupus and Sj(o)gren\u2019s syndrome: a long-term follow-up study","volume":"7","author":"Chen H","year":"2013","unstructured":"Chen H, Su J, Wang Q, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with lupus and Sj(o)gren\u2019s syndrome: a long-term follow-up study. Chin J Allergy Clin Immunol 2013; 7(2): 139\u2013145.","journal-title":"Chin J Allergy Clin Immunol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000273"},{"key":"e_1_3_4_27_2","first-page":"242","article-title":"Efficacy of low-dose rituximab in secondary thrombocytopenia in primary Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Zhao Y.","year":"2014","unstructured":"Zhao Y. Efficacy of low-dose rituximab in secondary thrombocytopenia in primary Sj\u00f6gren\u2019s syndrome. Guide China Med 2014; 15: 242\u2013243.","journal-title":"Guide China Med"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05152-x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.5414\/CP203453"},{"issue":"9","key":"e_1_3_4_30_2","first-page":"648","article-title":"Long-term efficacy and safety observation of low-dose short-course RTX therapy in 12 refractory CTD-ITP patients","volume":"38","author":"Zhou L","year":"2016","unstructured":"Zhou L, Qin W, Xin X, et al. Long-term efficacy and safety observation of low-dose short-course RTX therapy in 12 refractory CTD-ITP patients. Zhejiang Med 2016; 38(9): 648\u2013652.","journal-title":"Zhejiang Med"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24999"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07031-1"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110716"},{"issue":"6","key":"e_1_3_4_34_2","first-page":"902","article-title":"The treatment of refractory thrombocytopenia in primary Sj\u00f6gren\u2019s syndrome by cyclosporine A","volume":"15","author":"Chen L","year":"2008","unstructured":"Chen L, Sun H, Wu B, et al. The treatment of refractory thrombocytopenia in primary Sj\u00f6gren\u2019s syndrome by cyclosporine A. Clin Med J China 2008; 15(6): 902\u2013903.","journal-title":"Clin Med J China"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317711011"},{"issue":"12","key":"e_1_3_4_36_2","first-page":"2268","article-title":"Tacrolimus therapy in primary Sj\u00f6gren\u2019s syndrome with refractory immune thrombocytopenia: a retrospective study","volume":"40","author":"Xu R","year":"2022","unstructured":"Xu R, Yan Q, Gong Y, et al. Tacrolimus therapy in primary Sj\u00f6gren\u2019s syndrome with refractory immune thrombocytopenia: a retrospective study. Clin Exp Rheumatol 2022; 40(12): 2268\u20132274.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01248-1"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead160"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa645"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231160688"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4312-y"},{"key":"e_1_3_4_42_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71","journal-title":"BMJ"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000511759"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00138"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000599"},{"issue":"3","key":"e_1_3_4_46_2","article-title":"A practical perspective of the hematologic manifestations of systemic lupus erythematosus","volume":"14","author":"Santacruz JC","year":"2022","unstructured":"Santacruz JC, Mantilla MJ, Rueda I, et al. A practical perspective of the hematologic manifestations of systemic lupus erythematosus. Cureus 2022; 14(3): e22938.","journal-title":"Cureus"},{"issue":"1","key":"e_1_3_4_47_2","first-page":"4","article-title":"The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature","volume":"7","author":"Mohammadpour F","year":"2018","unstructured":"Mohammadpour F, Kargar M, Hadjibabaie M. The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature. J Res Pharm Pract 2018; 7(1): 4\u201312.","journal-title":"J Res Pharm Pract"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106895"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/548085"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100596"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00003-4"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218883"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23518"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9992086"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259481"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241241576"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261422963","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261422963","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261422963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:17Z","timestamp":1777591097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261422963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"alternative-id":["10.1177\/20406207261422963"],"URL":"https:\/\/doi.org\/10.1177\/20406207261422963","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207261422963"}}